We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Greenwich Lifesciences Inc
5 own
6 watching
Current Price
$19.84
$0.4
(2.06%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
114.24M
52-Week High
26.27
52-Week Low
6.8241
Average Volume
0.14M
Dividend Yield
--
P/E Ratio
--
Market Capitalization114.24M52-Week High26.2752-Week Low6.8241Average Volume0.14MDividend Yield--P/E Ratio--What does the Greenwich Lifesciences Inc do?
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
Read More
How much money does Greenwich Lifesciences Inc make?
News & Events about Greenwich Lifesciences Inc.
Business Wire
1month ago
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the Company), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today provided the following year end update. SABCS...
Zolmax
3 months ago
Greenwich LifeSciences, Inc. (NASDAQ:GLSI Get Rating) CEO Snehal Patel acquired 3,000 shares of the stock in a transaction that occurred on Friday, October 14th. The stock was acquired at an average price of $9.75 per share, for a total transaction of $29,250.00. Following the transaction, the chief...
Business Wire
5 months ago
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the Company), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the following: Phase III clinical...
Zolmax
8 months ago
Greenwich LifeSciences, Inc. (NASDAQ:GLSI Get Rating) CEO Snehal Patel acquired 6,774 shares of Greenwich LifeSciences stock in a transaction on Thursday, June 2nd. The shares were purchased at an average cost of $7.38 per share, for a total transaction of $49,992.12. Following the acquisition, the ...
Ticker Report
9 months ago
Greenwich LifeSciences, Inc. (NASDAQ:GLSI Get Rating) insider Frank Joseph Daugherty bought 1,000 shares of the firms stock in a transaction on Monday, April 25th. The stock was purchased at an average cost of $16.25 per share, with a total value of $16,250.00. Following the ...
Frequently Asked Questions
Frequently Asked Questions
What is Greenwich Lifesciences Inc share price today?
Can Indians buy Greenwich Lifesciences Inc shares?
How can I buy Greenwich Lifesciences Inc shares from India?
Can Fractional shares of Greenwich Lifesciences Inc be purchased?
What are the documents required to start investing in Greenwich Lifesciences Inc stocks?
What is today’s traded volume of Greenwich Lifesciences Inc?
What is today’s market capitalisation of Greenwich Lifesciences Inc?
What is the 52-Week High and Low Range of Greenwich Lifesciences Inc?
What percentage is Greenwich Lifesciences Inc down from its 52-Week High?
What percentage is Greenwich Lifesciences Inc up from its 52-Week Low?
Current Price
$19.84
$0.4
(2.06%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.